Scisparc Ltd (SPRC)

$1.40 +0.01 (0.72%)
Market Cap 743,000.00
Revenue (ttm) 1.31M
Net Income (ttm) -6.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -479.39%
Debt to Equity Ratio -30.38
Volume 54,800
Avg Vol 1,537,680
Day's Range N/A - N/A
Shares Out 535,000.00
Stochastic %K 8%
Beta 1.67
Analysts Strong Buy
Price Target $20.00

Company Profile

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. It also sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufac...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 7 334 47180
Address:
Tower A, 2nd Floor 20 Raul Wallenberg Street, Tel Aviv, Israel
MovingFast77
MovingFast77 Dec. 23 at 8:10 PM
$SPRC Quantum added 3000 shares. #lowfloat Will create a #Shortsqueeze Merry Christmas Quantum play. $TSLA
0 · Reply
MovingFast77
MovingFast77 Dec. 23 at 5:48 PM
$SPRC end of year tax right off. January stock will rise buyers come in and get a deal
0 · Reply
looking4financialfreedom
looking4financialfreedom Dec. 23 at 2:57 PM
$SPRC What the hell???
0 · Reply
MovingFast77
MovingFast77 Dec. 22 at 6:24 PM
$SPRC still opportunity
0 · Reply
rangervs
rangervs Dec. 22 at 4:10 PM
$SPRC how is this staying down! Should be $2.50+! $LUCY same thing $3+
0 · Reply
MovingFast77
MovingFast77 Dec. 17 at 2:39 PM
$SPRC today
0 · Reply
MovingFast77
MovingFast77 Dec. 17 at 10:17 AM
$SPRC today is the day
0 · Reply
mkinvestinggroup
mkinvestinggroup Dec. 17 at 8:13 AM
$SPRC
0 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Dec. 16 at 2:28 PM
🌅 Watchlist part 2 ✅ $BDRX low $6.00 support; if above $6.20, has potential to $6.70 / $7.00 ✅ $AZI $1.60 support; if above $2.00, has potential to $2.20 / $2.30 ✅ $ORGO low $5.00 support; if above $5.60, has potential to $6.00 / $6.55 🚨 The above tickers are not ideal for swing accumulation at current prices 🚨 ✅ Ideal long entry near current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance ⏳ $SPRC • $VCIG still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N 💰, not GREED 🔥
0 · Reply
Love_To_Learn
Love_To_Learn Dec. 16 at 12:29 PM
$SPRC been lowering u
0 · Reply
Latest News on SPRC
SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

Dec 2, 2025, 9:29 AM EST - 22 days ago

SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

Dec 2, 2025, 8:05 AM EST - 22 days ago

Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio

Dec 1, 2025, 8:32 AM EST - 23 days ago

SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio

SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems

Nov 26, 2025, 7:38 AM EST - 4 weeks ago

SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems

SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Nov 20, 2025, 6:42 AM EST - 4 weeks ago

SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Nov 19, 2025, 8:30 AM EST - 5 weeks ago

Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

CMND

SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio

Oct 24, 2025, 7:55 AM EDT - 2 months ago

SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio

SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

Oct 23, 2025, 4:03 PM EDT - 2 months ago

SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery

Oct 23, 2025, 8:55 AM EDT - 2 months ago

SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery

Scisparc Ltd. - Early Warning Regarding Acquisition Of Common Shares Of Neurothera Labs Inc.

Oct 22, 2025, 3:30 PM EDT - 2 months ago

Scisparc Ltd. - Early Warning Regarding Acquisition Of Common Shares Of Neurothera Labs Inc.

SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders

Oct 20, 2025, 7:41 AM EDT - 2 months ago

SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders

SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio

Oct 15, 2025, 7:05 AM EDT - 2 months ago

SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio

SciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors

Oct 6, 2025, 6:40 AM EDT - 2 months ago

SciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors

SciSparc: N2OFF Shareholders Approve Merger with SciSparc's Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

Sep 29, 2025, 4:03 PM EDT - 3 months ago

SciSparc: N2OFF Shareholders Approve Merger with SciSparc's Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

SciSparc Stock Surges As It Launches Initiative To Advance Drug Discovery With Quantum Algorithms

Sep 25, 2025, 1:06 PM EDT - 3 months ago

SciSparc Stock Surges As It Launches Initiative To Advance Drug Discovery With Quantum Algorithms

SciSparc Resolves to Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize AI Drug Discovery

Sep 25, 2025, 7:05 AM EDT - 3 months ago

SciSparc Resolves to Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize AI Drug Discovery

SciSparc: AutoMax's Shareholders Approve Merger with SciSparc

Aug 28, 2025, 9:24 AM EDT - 4 months ago

SciSparc: AutoMax's Shareholders Approve Merger with SciSparc

SciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel

Aug 28, 2025, 6:45 AM EDT - 4 months ago

SciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel

SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

Aug 7, 2025, 7:32 AM EDT - 4 months ago

SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC

Jul 30, 2025, 4:34 PM EDT - 5 months ago

SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

Jul 30, 2025, 8:12 AM EDT - 5 months ago

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification

Jul 22, 2025, 7:32 AM EDT - 5 months ago

SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification

SciSparc Announces 1-for-21 Reverse Share Split

Jun 24, 2025, 5:03 PM EDT - 6 months ago

SciSparc Announces 1-for-21 Reverse Share Split

SciSparc Announces Publication of Japanese Patent Application

May 27, 2025, 7:32 AM EDT - 7 months ago

SciSparc Announces Publication of Japanese Patent Application

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

Apr 25, 2025, 7:59 AM EDT - 8 months ago

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

CMND

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

Mar 3, 2025, 8:25 AM EST - 10 months ago

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles

Feb 27, 2025, 8:45 AM EST - 10 months ago

SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles

SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology

Feb 18, 2025, 7:17 AM EST - 11 months ago

SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

Feb 4, 2025, 9:00 AM EST - 11 months ago

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

Jan 15, 2025, 7:34 AM EST - 1 year ago

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles

Jan 13, 2025, 8:41 AM EST - 1 year ago

SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles

SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results

Jan 7, 2025, 7:25 AM EST - 1 year ago

SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results

Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?

Jan 6, 2025, 11:04 AM EST - 1 year ago

Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?

SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

Jan 6, 2025, 7:50 AM EST - 1 year ago

SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

Dec 31, 2024, 9:24 AM EST - 1 year ago

SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

S&P 500 Edges Lower, SciSparc Shares Surge

Dec 26, 2024, 2:36 PM EST - 1 year ago

S&P 500 Edges Lower, SciSparc Shares Surge

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

Dec 26, 2024, 6:46 AM EST - 1 year ago

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company

Dec 16, 2024, 7:40 AM EST - 1 year ago

SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company

SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment

Sep 30, 2024, 9:25 AM EDT - 1 year ago

SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment

SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX

Sep 26, 2024, 9:05 AM EDT - 1 year ago

SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX

SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment

Sep 23, 2024, 8:17 AM EDT - 1 year ago

SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment

SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment

Sep 18, 2024, 4:09 PM EDT - 1 year ago

SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment

SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy

Sep 16, 2024, 4:06 PM EDT - 1 year ago

SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy

SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax's Direct Import Agreement with Major Chinese Vehicle Manufacturer

Sep 11, 2024, 7:40 AM EDT - 1 year ago

SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax's Direct Import Agreement with Major Chinese Vehicle Manufacturer

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

Sep 6, 2024, 7:55 AM EDT - 1 year ago

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination

Aug 29, 2024, 4:25 PM EDT - 1 year ago

SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination

SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million

Aug 28, 2024, 8:55 AM EDT - 1 year ago

SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million

SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome

Aug 23, 2024, 4:09 PM EDT - 1 year ago

SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome

SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board

Aug 22, 2024, 8:12 AM EDT - 1 year ago

SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board

SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment

Aug 19, 2024, 4:11 PM EDT - 1 year ago

SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment

MovingFast77
MovingFast77 Dec. 23 at 8:10 PM
$SPRC Quantum added 3000 shares. #lowfloat Will create a #Shortsqueeze Merry Christmas Quantum play. $TSLA
0 · Reply
MovingFast77
MovingFast77 Dec. 23 at 5:48 PM
$SPRC end of year tax right off. January stock will rise buyers come in and get a deal
0 · Reply
looking4financialfreedom
looking4financialfreedom Dec. 23 at 2:57 PM
$SPRC What the hell???
0 · Reply
MovingFast77
MovingFast77 Dec. 22 at 6:24 PM
$SPRC still opportunity
0 · Reply
rangervs
rangervs Dec. 22 at 4:10 PM
$SPRC how is this staying down! Should be $2.50+! $LUCY same thing $3+
0 · Reply
MovingFast77
MovingFast77 Dec. 17 at 2:39 PM
$SPRC today
0 · Reply
MovingFast77
MovingFast77 Dec. 17 at 10:17 AM
$SPRC today is the day
0 · Reply
mkinvestinggroup
mkinvestinggroup Dec. 17 at 8:13 AM
$SPRC
0 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Dec. 16 at 2:28 PM
🌅 Watchlist part 2 ✅ $BDRX low $6.00 support; if above $6.20, has potential to $6.70 / $7.00 ✅ $AZI $1.60 support; if above $2.00, has potential to $2.20 / $2.30 ✅ $ORGO low $5.00 support; if above $5.60, has potential to $6.00 / $6.55 🚨 The above tickers are not ideal for swing accumulation at current prices 🚨 ✅ Ideal long entry near current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance ⏳ $SPRC • $VCIG still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N 💰, not GREED 🔥
0 · Reply
Love_To_Learn
Love_To_Learn Dec. 16 at 12:29 PM
$SPRC been lowering u
0 · Reply
mkinvestinggroup
mkinvestinggroup Dec. 16 at 9:12 AM
$SPRC so quiet here 😅
0 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Dec. 16 at 4:33 AM
🌅 Watchlist part 2 ✅ $VERO low 2 support; if above 2.50, has potential to 3.00 / 3.40. Top after-hours mover — CONGRATS if you got in during swing accumulation, up +47% ✅ $INBS 1/10 reverse split, new price ~5.90 ✅ $STAI 1/20 reverse split, new price ~4.00 🚨 The above tickers are NOT ideal for swing accumulation at current price 🚨 ✅ Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance ⏳ $SPRC, $VCIG still in swing accumulation phase 🎯🎯 Goal is GREEN, not GREED
0 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Dec. 15 at 2:27 PM
🌅 Watchlist part 3 ✅ $ACB low $5.00 support; if above $5.50, has potential to $6.00 / $6.50 ✅ $SNDL low $2.00 support; if above $2.20, has potential to $2.60 / $2.80 ✅ $CRON low $3.00 support; if above $3.50, has potential to $4.00 / $4.50 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 ✅ Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance ⏳ $SPRC $VCIG still in swing accumulation phase 🎯🎯 Goal is GREEN 💰, not GREED 🔥
1 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Dec. 15 at 4:40 AM
🌅 watchlist part 2 📣 Cannabis tickers continue lighting up scanners following reports that Trump may consider to rescheduling from Schedule I to Schedule III ✅ $IMCC low $2.00 support; if above $2.20, has potential to $2.50 / $2.80 ✅ $SNDL low $2.00 support; if above $2.20, has potential to $2.60 / $2.80 ✅ $CRON low $3.00 support; if above $3.50, has potential to $4.00 / $4.50 🚨 Not ideal for swing accumulation at current prices ✅ Ideal long entry near key support 🎯 Stop if below support 🚨 Avoid chasing into strength near resistance ⌛️⏳ $SPRC $VCIG still in swing accumulation phase 🎯🎯 Goal is GREEN, not GREED
0 · Reply
MovingFast77
MovingFast77 Dec. 12 at 2:59 PM
$SPRC she's about to blow
0 · Reply
Love_To_Learn
Love_To_Learn Dec. 12 at 12:36 PM
$SPRC need u to cover some holes for now for the sls folks ok anyway i did creap up the ogi kids what say u ?
0 · Reply
rangervs
rangervs Dec. 11 at 9:48 PM
$SPRC keep loading !
0 · Reply
Bullginn
Bullginn Dec. 11 at 9:02 PM
$SPRC added because of quantum exposure
0 · Reply
ThePunk
ThePunk Dec. 11 at 7:00 PM
$MIGI look at $SPRC can be the next low float runner
0 · Reply
ThePunk
ThePunk Dec. 11 at 3:01 PM
$SMX halted twice $MIGI has the potential to be the next SMX but on budget price rn. $SPRC will finally be next?
0 · Reply
ThePunk
ThePunk Dec. 11 at 2:33 PM
$MIGI crazyyy openinngg holyyy $SPRC can we get some vol 2?
0 · Reply
ThePunk
ThePunk Dec. 11 at 1:35 PM
$MIGI omg this is gonna be epic run buckle up.. lots of volume before the news on the pr even hits!!! $SPRC woke up this morning can it run tho?
0 · Reply